# Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State

> **NCT00861458** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 14 (actual)

## Conditions studied

- Hepatitis C Virus

## Interventions

- **DRUG:** Pharmacokinetics

## Key facts

- **NCT ID:** NCT00861458
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2009-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00861458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00861458, "Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT00861458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*